🇺🇸 FDA
Pipeline program

BI 1815368, BI 1815368 Placebo, BI 1815368

1485-0018

Phase 2 small_molecule active

Quick answer

BI 1815368, BI 1815368 Placebo, BI 1815368 for Centre-involved diabetic macular edema is a Phase 2 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim International GmbH
Indication
Centre-involved diabetic macular edema
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials